With Hologic, Inc. HOLX gearing up to release its fiscal 2025 first-quarter financial results on Feb. 5 after the market closes, the company’s Breast Health segment is expected to have benefited from ...

HOLX's Breast Health unit is back in focus as a proposed Blackstone-TPG deal adds a $76 cash offer and CVR to 2026-27 revenue goals.

Q3 2025 revenue is projected at $1 billion to $1.01 billion, with non-GAAP EPS guidance between $1.04 and $1.07. Full-year revenue guidance is maintained at $4.05 billion to $4.10 billion, despite a ...

Hologic, Inc.’s HOLX GYN Surgical performance is expected to be driven by a robust international business and sales of MyoSure and the related Fluent system. The Breast Health division is likely to ...

May 1 (Reuters) - Medical equipment maker Hologic (HOLX.O), opens new tab lowered its fiscal 2025 profit forecast, citing uncertainty around the tariffs imposed by U.S. President Donald Trump's ...

Last week, Hologic HOLX earned two key regulatory approvals. The company’s Affirm Contrast Biopsy software has earned the CE Mark, having previously been cleared by the FDA in October 2020. Meanwhile, ...

S&P expects the take-private deal to result in adjusted leverage of approximately 8.4x in fiscal 2026, a significant increase from just 0.3x in fiscal 2025. The transaction reflects a shift from ...

The segment generates a bulk of service revenues from the service contracts related to the digital mammography portfolio. In the first quarter of fiscal 2025, robust breast imaging service revenues ...